Management of Left Atrial Myxoma
Surgical excision should be performed urgently once a left atrial myxoma is diagnosed, as it is the only definitive treatment and prevents life-threatening complications including sudden death, stroke, and cardiac obstruction. 1, 2, 3
Immediate Management Priorities
Urgent Surgical Resection (Class I Recommendation)
All symptomatic left atrial myxomas require immediate surgical resection to prevent catastrophic complications, with surgery recommended as soon as the diagnosis is established 1, 2, 4
Complete tumor excision with an adequate margin of atrial septum is essential to minimize recurrence risk (which occurs in 1-5% of sporadic cases and up to 3% overall) 1, 5
The biatrial surgical approach is preferred because it allows inspection of all four cardiac chambers, limits tumor manipulation during removal, and facilitates complete excision 4
Surgical mortality is extremely low when performed at experienced centers, with most patients achieving excellent long-term outcomes 4, 6
Why Surgery Cannot Be Delayed
The overall embolism rate is 25%, with embolic stroke being the presenting symptom in up to 50% of myxoma cases 1, 2
Myxomas with villous or papillary surface architecture have markedly higher embolic potential due to their friable surfaces that generate thrombus and shed tumor fragments 1, 3
Mechanical obstruction can occur acutely, particularly if interstitial hemorrhage within the tumor causes rapid expansion and acute mitral valve obstruction 7
Sudden death from complete valvular obstruction remains a risk until the tumor is removed 2, 6
Pre-Operative Diagnostic Evaluation
Essential Imaging
Transthoracic and transesophageal echocardiography (TEE) are the diagnostic modalities of choice, with TEE offering superior sensitivity for detecting cardiac tumors and characterizing tumor morphology 1, 2, 3
Cardiac MRI or CT should be obtained for surgical planning to provide additional anatomic characterization, particularly regarding tumor attachment and size 1, 2
Coronary angiography should be performed in older patients at risk for coronary artery disease, as concomitant coronary artery bypass may be needed 4
Key Anatomic Features to Document
- Location and attachment site (most commonly the interatrial septum at the fossa ovalis) 1, 2
- Tumor size, mobility, and surface characteristics (villous features indicate higher embolic risk) 1, 3
- Presence of mitral valve obstruction or regurgitation 2
What NOT to Do: Critical Pitfalls
Anticoagulation Alone is Inadequate
Anticoagulation or antiplatelet therapy alone does not prevent embolic complications and fails to address the mechanical obstruction caused by the tumor 1, 3
Anticoagulation should not be used as definitive therapy and may increase bleeding risk without providing benefit 2
Avoid Pericardiocentesis
- Do not perform pericardiocentesis if pericardial effusion is present, as this may worsen hemodynamics 2
Do Not Delay for Medical Optimization
- Surgery should not be postponed for extensive medical optimization given the high risk of sudden catastrophic events 4, 6
Post-Operative Management
Histopathologic Confirmation
Mandatory histopathologic examination should confirm the diagnosis and identify characteristic features including myxoma cells (lepidic cells), abundant myxoid matrix, and vascular channels 1, 2
Immunohistochemistry is positive for vimentin and calretinin; negative for cytokeratin and S100 1
Long-Term Surveillance
Periodic echocardiographic follow-up is mandatory to monitor for recurrence, particularly in the first several years after surgery 1, 4, 5
Recurrence occurs in 1-5% of sporadic cases but is higher in familial myxomas, necessitating lifelong surveillance 1, 5
Clinical follow-up should continue indefinitely, as late recurrences have been reported even years after initial resection 4, 5
Special Clinical Scenarios
Cryptogenic Stroke Presentation
In younger patients with cryptogenic stroke, TEE should be obtained to evaluate for left atrial myxoma as a cardiac source of embolism 1, 3
Urgent surgical resection reduces recurrent stroke risk (Class IIa recommendation, Level of Evidence C-LD) 3